Robert Kilkuskie
Directeur/Membre du Conseil chez Michigan High Throughput Screening Center
Postes actifs de Robert Kilkuskie
Sociétés | Poste | Début | Fin |
---|---|---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Directeur/Membre du Conseil | - | - |
National Institute of Health Policy | Corporate Officer/Principal | 30/04/2010 | - |
Historique de carrière de Robert Kilkuskie
Statistiques
Internationale
Etats-Unis | 3 |
Opérationnelle
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Michigan High Throughput Screening Center
Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties. | Commercial Services |
National Institute of Health Policy |
- Bourse
- Insiders
- Robert Kilkuskie
- Expérience